Vorinostat
Vorinostat (also known as SAHA) is a prescription HDAC inhibitor originally developed/used in oncology contexts. HDAC inhibitors change gene expression broadly by altering histone acetylation state, which is why they're sometimes discussed in "epigenetic reset" theories.
-
This page summarizes anecdotal reports and community observations, not medical evidence. Reports may be incomplete, biased or inaccurate and are not medical advice or recommendations. “Risk” here refers to how frequently severe or prolonged symptom worsening is reported, not to proven causation or population-wide probability. Individual responses vary widely, and absence of issues in some users does not rule out significant reactions in others.
-
Within PFS/PSSD/PAS communities, vorinostat is discussed in relation to its potential interactions with epigenetic regulation and gene expression pathways. HDAC inhibitors change gene expression broadly by altering histone acetylation state, which is why they're sometimes discussed in "epigenetic reset" theories. In PFS/PSSD/PAS circles, vorinostat comes up specifically because some hypotheses frame these syndromes as involving durable, "stuck" transcriptional states—so a drug that can shift gene-expression programs is sometimes viewed (speculatively) as a potential lever. These mechanisms may interact with pathways involving gene expression, epigenetic regulation, or transcriptional control that are often discussed in relation to PFS / PSSD / PAS.
-
Reports of Severe and Sometimes Lasting Worsening (for PFS/PSSD/PAS):
Among individuals who already have PFS/PSSD/PAS, vorinostat is approached with significant caution as it has been cited in community reports as preceding symptom worsening, with there being accounts describing both longer-lasting declines in baseline. Overall, the pattern reads as high downside with little consistent upside, despite the theoretical appeal of HDAC/epigenetic mechanisms. Because vorinostat can shift gene expression widely and carries meaningful systemic risks, many in these communities treat it as a "do-not-self-experiment" category. In light of this pattern, many within the community view vorinostat as carrying a meaningful risk for those with established PFS/PSSD/PAS, even in the absence of controlled data.
For individuals without these conditions, vorinostat is a prescription oncology medication with significant toxicity and side-effect profiles.
Evidence basis: Established pharmacology and safety profile of vorinostat (HDAC inhibition); theoretical discussions around epigenetics/gene expression; anecdotal reports (online forums, group self-reports); no controlled studies demonstrate safety or efficacy for PFS/PSSD/PAS.
-
Public comments reflect individual experiences and opinions. They are not medical advice and may not be accurate or representative.